Inhibitory Effect of YC-1, 3-(5′-Hydroxymethyl-2′-Furyl)-1-Benzylindazole, on Experimental Choroidal Neovascularization in Rat

Purpose: It was the aim of this study to evaluate the effects of YC-1, 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole, one of the hypoxia-inducible factor 1 (HIF-1) inhibitors, on laser-induced choroidal neovascularization (CNV) in rats. Methods: Thirty female Brown Norway rats underwent laser photocoagulation to induce CNV. Twenty of them (treatment group) were treated with a single intravitreal injection of 5 µg YC-1, and the remaining 10 (control) were sham-treated with a single intravitreal injection of 2.5 mg/ml dimethyl sulfoxide 2 weeks after laser photocoagulation. The expression of HIF-1α and vascular endothelial growth factor (VEGF) in CNV was evaluated by immunofluorescence staining. Fluorescein angiography was performed 2 weeks before and 2 weeks after single intravitreal YC-1 (5 µg) and dimethyl sulfoxide (2.5 mg/ml) injection, grading fluorescein leakage from 0 to 3. The size of the CNV was measured on histologic sections. Results: Both HIF-1α and VEGF were expressed in CNV lesions in the control group 4 weeks after laser photocoagulation, whereas the expressions of HIF-1α and VEGF were not observed in the intravitreally YC-1-treated group. The mean fluorescein leakage score decreased from 2.56 ± 0.49 to 0.79 ± 0.71 in the intravitreally YC-1-injected group and from 2.62 ± 0.49 to 1.58 ± 0.60 in the control group. Sixty-eight (71.6%) out of 95 CNV lesions of intravitreally YC-1-treated eyes (71.4%) and 12 (21.8%) out of 55 lesions in DMSO-treated eyes showed a decreased fluorescein leakage score of 2 or more. The mean difference of fluorescein leakage scores between the intravitreally YC-1-treated group and the control group was significant (p = 0.004). The mean thickness of the CNV lesions in the intravitreally YC-1-treated group (27.30 ± 6.47 µm) was smaller than that of the control group (64.36 ± 8.26 µm, p < 0.001). There was no ocular inflammation, retina hemorrhage or systemic toxicity induced by YC-1 treatment. Conclusion: These results suggest that YC-1 inhibits the HIF-1 expression after photocoagulation and suppresses the development of laser-induced CNV formation.

[1]  H. Gu,et al.  Effects of YC-1 on Hypoxia-Inducible Factor 1-Driven Transcription Activity, Cell Proliferative Vitality, and Apoptosis in Hypoxic Human Pancreatic Cancer Cells , 2007, Pancreas.

[2]  R. Deberardinis,et al.  The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. , 2007, Genes & development.

[3]  Jong-Wan Park,et al.  A domain responsible for HIF-1α degradation by YC-1, a novel anticancer agent , 2006 .

[4]  S. Kuo,et al.  Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells. , 1995, The Biochemical journal.

[5]  C. Teng,et al.  Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. , 2001, Biochemical pharmacology.

[6]  Jinho Kim,et al.  YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. , 2003, Journal of the National Cancer Institute.

[7]  Jinho Kim,et al.  YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. , 2006, Cancer research.

[8]  F. Lee,et al.  YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-κB signaling to HIF-1α accumulation during hypoxia , 2007, Oncogene.

[9]  P. Campochiaro,et al.  Implication of the hypoxia response element of the vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development , 2006, Journal of cellular physiology.

[10]  G. Ying,et al.  Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. , 2005, Investigative ophthalmology & visual science.

[11]  G. Semenza.  HIF-1: mediator of physiological and pathophysiological responses to hypoxia. , 2000, Journal of applied physiology.

[12]  Joan W. Miller,et al.  Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. , 2002, Archives of ophthalmology.

[13]  J. Gimble,et al.  Effects of prolyl hydroxylase inhibitors on adipogenesis and hypoxia inducible factor 1 alpha levels under normoxic conditions , 2007, Journal of cellular biochemistry.

[14]  J. Stasch,et al.  BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase. , 2002, Biochemical and biophysical research communications.

[15]  N. Bressler,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.

[16]  F L Ferris,et al.  Senile macular degeneration: a case-control study. , 1983, American journal of epidemiology.

[17]  C. Wanner,et al.  Effects of the soluble guanylyl cyclase activator, YC‐1, on vascular tone, cyclic GMP levels and phosphodiesterase activity , 1999, British journal of pharmacology.

[18]  A. Ho,et al.  Foveolar choroidal blood flow in age-related macular degeneration. , 1998, Investigative ophthalmology & visual science.

[19]  D. Hinton,et al.  Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. , 1996, Investigative ophthalmology & visual science.

[20]  S. Kuo,et al.  YC-1 [3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl Indazole] Inhibits Endothelial Cell Functions Induced by Angiogenic Factors in Vitro and Angiogenesis in Vivo Models , 2005, Journal of Pharmacology and Experimental Therapeutics.

[21]  G. Schultz,et al.  YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. , 1998, Molecular pharmacology.

[22]  R. Danis,et al.  Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. , 2001, Archives of ophthalmology.

[23]  N. Bazan,et al.  Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. , 2003, Investigative ophthalmology & visual science.

[24]  S. Kuo,et al.  YC-1, a novel activator of platelet guanylate cyclase. , 1994, Blood.

[25]  Yu-Chih Liang,et al.  YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway. , 2003, Biochemical pharmacology.

[26]  P. Campochiaro,et al.  VEGF is major stimulator in model of choroidal neovascularization. , 2000, Investigative ophthalmology & visual science.

[27]  K. Dutt,et al.  Vasculotropin/Vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultued in vitro , 1995, Journal of cellular physiology.